Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Antidepressive agents: benefits/risks]

H Cuche1, A Gérard

  • 1SHU, Hôpital Sainte-Anne, Paris.

L'Encephale
|April 1, 1994
PubMed
Summary
This summary is machine-generated.

Assessing antidepressant efficacy for mood disorders is complex due to evolving diagnoses and economic factors. Patient-physician relationships and societal influences impact the risk-benefit analysis of these medications.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Travel to South Africa by a patient on anti-TNF: Could tuberculosis have been prevented?]

Revue des maladies respiratoires·2025
Same author

[Ruxolitinib, disseminated tuberculosis and primary myelofibrosis: A case study].

Revue des maladies respiratoires·2025
Same author

30 years of ocular proton therapy, the Nice view.

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2022
Same author

Ocular proton therapy, pencil beam scanning high energy proton therapy or stereotactic radiotherapy for uveal melanoma; an in silico study.

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2022
Same author

PROPENSIX: pressure garment therapy using compressive dynamic Lycra<sup>®</sup> sleeve to improve bi-manual performance in unilateral cerebral palsy: a multicenter randomized controlled trial protocol.

Trials·2022
Same author

[Hemorrhagic bullous dermatosis (HBD): A rare side-effect of heparins].

Annales de dermatologie et de venereologie·2020
Same journal

Measuring antidepressant side effects in military personnel - Clinical validation of the French version of the UKU-SERS-Pat Scale: A comparative study of patient and clinician ratings.

L'Encephale·2026
Same journal

[Empowerment in addictology].

L'Encephale·2026
Same journal

Evaluation of the links between smoking and conspiracy mentality.

L'Encephale·2026
Same journal

Use of a relevance assessment tool in therapeutic residential care: A real world study.

L'Encephale·2026
Same journal

Prevalence and characteristics of domestic violence in a sample of adult psychiatric outpatients: A cross-sectional study.

L'Encephale·2026
Same journal

From representations to practice: how professionals describe supporting parents with psychiatric or somatic illness or disability.

L'Encephale·2026
See all related articles

Area of Science:

  • Psychiatry and Pharmacology
  • Clinical Psychology
  • Health Economics

Context:

  • The 1994 landscape of mood disorder treatment presented challenges in evaluating antidepressant risk-benefit ratios.
  • Nosographical shifts created new diagnostic categories like subsyndromal depression and mixed anxiety-depression (ICD 10).
  • Economic and medical assessment evolution shifted focus from individual patient-physician evaluations to group-based indices.

Purpose:

  • To critically examine the complexities in assessing the risk-benefit ratio of antidepressant drugs for mood disorders.
  • To analyze the impact of evolving diagnostic criteria and economic pressures on clinical practice.
  • To explore the influence of sociological factors on the perception and use of antidepressants.

Summary:

Related Experiment Videos

  • Frequent diagnostic changes and the emergence of new clinical entities complicate the established link between antidepressants and typical depression.
  • The shift towards group-based economic assessments overshadows individualized risk-benefit evaluations crucial in the patient-physician relationship.
  • Antidepressants are sometimes marketed for secondary effects, leading to unclear treatment strategies and duration.

    • Impact:

    • Highlights the need for nuanced approaches to antidepressant risk-benefit assessment in diverse mood disorder presentations.
    • Underscores the importance of preserving the patient-physician relationship in treatment decisions.
    • Calls for clearer guidelines on antidepressant use, particularly concerning off-label indications and treatment duration.